Media Coverage
UBIP has completed the submission for its in-house developed biosimilar drug (UB-851, EPO) to TFDA
UBI Pharma Inc. (6562.TW) has completed the application for drug inspection registration and submission of Taiwanese drug certificates to the Taiwan Food and Drug Administration (TFDA) for its in-house developed biosimilar drug, UB-851, a recombinant human erythropoietin (EPO).
UBI Pharma Inc.'s "Single-Chain Immunoglobulin Fusion Protein Technology" has been granted a patent in the USA
UBI Pharma Inc. (6562.TW) has been granted a patent [US Patent Granted US 11,820,807 B2] by the United States Patent and Trademark Office (USPTO) for its "Single-Chain Immunoglobulin Fusion Protein Technology." This technology extends the duration of drug efficacy and can significantly enhance the effectiveness of cancer treatment, either independently or in combination with existing anticancer therapies.
Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc. to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market
Merdury Biopharmaceutical Corporation has forged a strategic collaboration with UBI Pharma Inc. (6562-TW) to co-develop and manufacture Sildenafil Citrate Orally Disintegrating Tablets 50mg, referred to as sildenafil orally disintegrating tablets. This collaboration integrates Merdury Biopharmaceutical's cutting-edge 3D powder printing pharmaceutical equipment and drug formulation technology into UBI Pharma's GMP pharmaceutical factory, initiating drug trial production, facilitating global drug certifications, and establishing a robust, long-term partnership.
UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023)
UBI Pharma Inc. (6562.TW) has received two prestigious awards at the 20th National Brand Yushan Awards：the Best Product Category Award for its HIV Combination Tablet (NDF01) and the Outstanding Corporate Leader Award for its Chairman and CEO.
UBI Pharma Inc. has commissioned EirGenix to produce the biosimilar drug UB-851, paving the way for an early international market expansion.
UBI Pharma Inc. (6562.TW) announced that its self-developed erythropoietin biosimilar drug, UB-851, has signed a production agreement with EirGenix, officially initiating its international market expansion.
UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market
UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market.
The Phase III Trial of the EPO Injection Developed by UBI Pharma Inc. has been Completed, the Company Plans to Submit an Application for Drug Licensing to the TFDA
UBI Pharma Inc. (6562.TW) announced the results of Phase III Trial of the end-of-stage data analysis of the phase III clinical trial of its erythropoietin biosimilar drug UB-851 showed that the results met expectations.
Successful Unblinding of the Phase III Clinical Trial of Erythropoietin Conducted by UBI Pharma Inc.
UBI Pharma Inc. announced today (June 11th) that the unblinding of the interim data of the phase III clinical trial of erythropoietin UBI-851 has been completed, and the mean change in the hemoglobin levels as the primary efficacy endpoint was statistically significant and met expectations for the trial. The application for drug license in Taiwan will be submitted thereafter.
The Unique Long-acting Technology Platform Developed by UBI Pharma Inc. Has Been Granted a Patent by the United States and Canada
The Polysaccharide-binding Fusion Protein Platform is a long-acting drug technology platform developed independently by UBI Pharma Inc. (6562.TW), and has been patented in Canada and China. Now, the company has announced on October 2 that the United States Patent and Trademark Office (USPTO) has issued the patent certificate for the platform.
TFDA Approves the Phase I Clinical Trial of the New Drug UB-852 Developed by UBI Pharma Inc.
UBI Pharma Inc. (6562.TW) announced that the TFDA has approved the phase I clinical trial of its innovative, long-acting recombinant human erythropoietin UB-852.
TFDA Approves the Phase I Clinical Trial of the New Targeted Anticancer Drug UB-941 Developed by UBI Pharma Inc.
The investigational new drug (IND) application submitted by UBI Pharma Inc. (6562.TW) for the newly developed targeted anticancer drug UB-941 has been approved by the Taiwan Food and Drug Administration (TFDA), Ministry of Health and Welfare for the implementation of the phase I clinical trial. The trial is a multinational, multicenter, two-stage clinical trial. It is designed to investigate the safety and efficacy of the new drug in patients with solid tumors with mutations in the BRAF gene.